How CRISPR-Cas System Could Be Used to Combat Antimicrobial Resistance

References

• Matsuzaki S, Yasuda M, Nishikawa H, et al. Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage ϕMR11. J Infect Dis. 2003;187(4):613–624. doi:10.1086/37400112599078
   PubMed Web of Science ®Google Scholar
• Heo Y-J, Lee Y-R, Jung -H-H, Lee J, Ko G, Cho Y-H. Antibacterial efficacy of phages against pseudomonas aeruginosa infections in mice and drosophila melanogaster. Antimicrob Agents Chemother. 2009;53(6):2469–2474. doi:10.1128/AAC.01646-0819364866
   PubMed Web of Science ®Google Scholar
• Watanabe R, Matsumoto T, Sano G, et al. Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob Agents Chemother. 2007;51(2):446–452. doi:10.1128/AAC.00635-0617116686
   PubMed Web of Science ®Google Scholar
• Verhoef TI, Morris S. Cost‐effectiveness and pricing of antibacterial drugs. Chem Biol Drug Des. 2015;85(1):4–13. doi:10.1111/cbdd.1241725521641
   PubMed Web of Science ®Google Scholar
• Goren M, Yosef I, Qimron U. Sensitizing pathogens to antibiotics using the CRISPR-Cas system. Drug Resist Updates. 2017;30:1–6. doi:10.1016/j.drup.2016.11.001
   PubMed Web of Science ®Google Scholar
• Narenji H, Gholizadeh P, Aghazadeh M, Rezaee MA, Asgharzadeh M, Kafil HS. Peptide nucleic acids (PNAs): currently potential bactericidal agents. Biomed Pharmacother. 2017;93:580–588. doi:10.1016/j.biopha.2017.06.09228686972
   PubMed Web of Science ®Google Scholar
• Boucher HW, Scheld M, Bartlett J, et al. Bad bugs, no drugs: no ESKAPE! An update from the infectious diseases society of America. Clin Infect Dis. 2009;48(1):1–12. doi:10.1086/59501119035777
   PubMed Web of Science ®Google Scholar
• Yosef I, Manor M, Kiro R, Qimron U. Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria. Proc Natl Acad Sci. 2015;112(23):7267–7272. doi:10.1073/pnas.150010711226060300
   PubMed Web of Science ®Google Scholar
• Lin DM, Koskella B, Lin HC. Phage therapy: an alternative to antibiotics in the age of multi-drug resistance. World J Gastrointest Pharmacol Ther. 2017;8(3):162–173. doi:10.4292/wjgpt.v8.i3.16228828194
   PubMedGoogle Scholar
• Bai H, You Y, Yan H, et al. Antisense inhibition of gene expression and growth in gram-negative bacteria by cell-penetrating peptide conjugates of peptide nucleic acids targeted to rpoD gene. Biomaterials. 2012;33(2):659–667. doi:10.1016/j.biomaterials.2011.09.07522000398
   PubMed Web of Science ®Google Scholar
• Wright GD. Making sense of antisense in antibiotic drug discovery. Cell Host Microbe. 2009;6(3):197–198. doi:10.1016/j.chom.2009.08.00919748460
   PubMed Web of Science ®Google Scholar
• Singh SB, Phillips JW, Wang J. Highly sensitive target-based whole-cell antibacterial discovery strategy by antisense RNA silencing. Curr Opin Drug Discov Devel. 2007;10(2):160.
   PubMedGoogle Scholar
• Abdi SN, Ghotaslou R, Asgharzadeh M, et al. AdeB efflux pump gene knockdown by mRNA mediated peptide nucleic acid in multidrug resistance Acinetobacter baumannii. Microb Pathog. 2020;139:103825. doi:10.1016/j.micpath.2019.10382531706000
   PubMed Web of Science ®Google Scholar
• Narenji H, Teymournejad O, Rezaee MA, et al. Antisense peptide nucleic acids againstftsZ andefaA genes inhibit growth and biofilm formation of Enterococcus faecalis. Microb Pathog. 2020;139:103907. doi:10.1016/j.micpath.2019.10390731811888
   PubMed Web of Science ®Google Scholar
• Dastjerdeh MS, Kouhpayeh S, Sabzehei F, et al. Zinc finger nuclease: a new approach to overcome beta-lactam antibiotic resistance. Jundishapur J Microbiol. 2016;9(1).
   Web of Science ®Google Scholar
• Gupta RM, Musunuru K. Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9. J Clin Invest. 2014;124(10):4154–4161. doi:10.1172/JCI7299225271723
   PubMed Web of Science ®Google Scholar
• Gholizadeh P, Aghazadeh M, Asgharzadeh M, Kafil H. Suppressing the CRISPR/Cas adaptive immune system in bacterial infections. Eur J Clin Microbiol Infect Dis. 2017;36(11):2043–2051. doi:10.1007/s10096-017-3036-228601970
   PubMed Web of Science ®Google Scholar
• van Belkum A, Soriaga LB, LaFave MC, et al. Phylogenetic distribution of CRISPR-Cas systems in antibiotic-resistant Pseudomonas aeruginosa. MBio. 2015;6(6):e01796–15. doi:10.1128/mBio.01796-1526604259
   PubMed Web of Science ®Google Scholar
• Yao R, Liu D, Jia X, Zheng Y, Liu W, Xiao Y. CRISPR-Cas9/Cas12a biotechnology and application in bacteria. Synth Syst Biotechnol. 2018;3(3):135–149. doi:10.1016/j.synbio.2018.09.00430345399
   PubMed Web of Science ®Google Scholar
• Biswas B, Adhya S, Washart P, et al. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect Immun. 2002;70(1):204–210. doi:10.1128/IAI.70.1.204-210.200211748184
   PubMed Web of Science ®Google Scholar
• Bernhardt TG, Wang N, Struck DK, Young R. A protein antibiotic in the phage Qβ virion: diversity in lysis targets. Science. 2001;292(5525):2326–2329. doi:10.1126/science.105828911423662
   PubMed Web of Science ®Google Scholar
• Schuch R, Nelson D, Fischetti VA. A bacteriolytic agent that detects and kills Bacillus anthracis. Nature. 2002;418(6900):884. doi:10.1038/nature0102612192412
   PubMed Web of Science ®Google Scholar
• Loeffler JM, Nelson D, Fischetti VA. Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science. 2001;294(5549):2170–2172. doi:10.1126/science.106686911739958
   PubMed Web of Science ®Google Scholar
• Cao J, Sun Y-Q, Berglindh T, et al. Helicobacter pylori-antigen-binding fragments expressed on the filamentous M13 phage prevent bacterial growth. Biochim Biophys Acta Bioenerg. 2000;1474(1):107–113. doi:10.1016/S0304-4165(00)00005-2
   PubMed Web of Science ®Google Scholar
• Clark JR, March JB. Bacterial viruses as human vaccines? Expert Rev Vaccines. 2004;3(4):463–476. doi:10.1586/14760584.3.4.46315270651
   PubMedGoogle Scholar
• March JB, Clark JR, Jepson CD. Genetic immunisation against hepatitis B using whole bacteriophage lambda particles. Vaccine. 2004;22(13–14):1666–1671. doi:10.1016/j.vaccine.2003.10.04715068849
   PubMed Web of Science ®Google Scholar
• Jepson CD, March JB. Bacteriophage lambda is a highly stable DNA vaccine delivery vehicle. Vaccine. 2004;22(19):2413–2419. doi:10.1016/j.vaccine.2003.11.06515193403
   PubMed Web of Science ®Google Scholar
• Sully EK, Geller BL. Antisense antimicrobial therapeutics. Curr Opin Microbiol. 2016;33:47–55. doi:10.1016/j.mib.2016.05.01727375107
   PubMed Web of Science ®Google Scholar
• Singh P, Panda D. FtsZ inhibition: a promising approach for antistaphylococcal therapy. Drug News Perspect. 2010;23(5):295–304. doi:10.1358/dnp.2010.23.5.142948920603653
   PubMedGoogle Scholar
• Lopez C, Arivett BA, Actis LA, Tolmasky ME. Inhibition of AAC (6′)-Ib-mediated resistance to amikacin in Acinetobacter baumannii by an antisense peptide-conjugated 2′, 4′-bridged nucleic acid-NC-DNA hybrid oligomer. Antimicrob Agents Chemother. 2015;59(9):5798–5803. doi:10.1128/AAC.01304-1526169414
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhao H, Cheng CH. Mutagenesis in Xenopus and Zebrafish Using TALENs. Springer; 2016:207–227.
   Google Scholar
• Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD. Genome editing with engineered zinc finger nucleases. Nat Rev Genet. 2010;11(9):636. doi:10.1038/nrg284220717154
   PubMed Web of Science ®Google Scholar
• Holkers M, Maggio I, Liu J, et al. Differential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene transfer into human cells. Nucleic Acids Res. 2012;41(5):e63–e. doi:10.1093/nar/gks144623275534
   PubMed Web of Science ®Google Scholar
• Rémy S, Tesson L, Ménoret S, Usal C, Scharenberg AM, Anegon I. Zinc-finger nucleases: a powerful tool for genetic engineering of animals. Transgenic Res. 2010;19(3):363–371. doi:10.1007/s11248-009-9323-719821047
   PubMed Web of Science ®Google Scholar
• Rouet P, Smih F, Jasin M. Expression of a site-specific endonuclease stimulates homologous recombination in mammalian cells. Proc Natl Acad Sci. 1994;91(13):6064–6068. doi:10.1073/pnas.91.13.60648016116
   PubMed Web of Science ®Google Scholar
• Kang YK, Kwon K, Ryu JS, Lee HN, Park C, Chung HJ. Nonviral genome editing based on a polymer-derivatized CRISPR nanocomplex for targeting bacterial pathogens and antibiotic resistance. Bioconjug Chem. 2017;28(4):957–967. doi:10.1021/acs.bioconjchem.6b0067628215090
   PubMed Web of Science ®Google Scholar
• Müller V, Rajer F, Frykholm K, et al. Direct identification of antibiotic resistance genes on single plasmid molecules using CRISPR/Cas9 in combination with optical DNA mapping. Sci Rep. 2016;6:37938. doi:10.1038/srep3793827905467
   PubMed Web of Science ®Google Scholar
• Price VJ, McBride SW, Duerkop B, Palmer KL. CRISPR-Cas blocks antibiotic resistance plasmid transfer between Enterococcus faecalis strains in the gastrointestinal tract. bioRxiv. 2018;312751.
   Google Scholar
• Touchon M, Charpentier S, Pognard D, et al. Antibiotic resistance plasmids spread among natural isolates of Escherichia coli in spite of CRISPR elements. Microbiology. 2012;158(12):2997–3004. doi:10.1099/mic.0.060814-0
   Web of Science ®Google Scholar
• Zhang H, Cheng Q-X, Liu A-M, Zhao G-P WJ. A novel and efficient method for bacteria genome editing employing both CRISPR/Cas9 and an antibiotic resistance cassette. Front Microbiol. 2017;8:812. doi:10.3389/fmicb.2017.0081228529507
   PubMed Web of Science ®Google Scholar
• Barrangou R, Fremaux C, Deveau H, et al. CRISPR provides acquired resistance against viruses in prokaryotes. Science. 2007;315(5819):1709–1712. doi:10.1126/science.113814017379808
   PubMed Web of Science ®Google Scholar
• Goren M, Yosef I, Edgar R, Qimron U. The bacterial CRISPR/Cas system as analog of the mammalian adaptive immune system. RNA Biol. 2012;9(5):549–554. doi:10.4161/rna.2017722614830
   PubMed Web of Science ®Google Scholar
• Hussain W, Mahmood T, Hussain J, et al. CRISPR/Cas system: a game changing genome editing technology, to treat human genetic diseases. Gene. 2019;685:70–75. doi:10.1016/j.gene.2018.10.07230393194
   PubMed Web of Science ®Google Scholar
• Jiang W, Bikard D, Cox D, Zhang F, Marraffini LA. RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nat Biotechnol. 2013;31(3):233. doi:10.1038/nbt.250823360965
   PubMed Web of Science ®Google Scholar
• Feng Z, Zhang B, Ding W, et al. Efficient genome editing in plants using a CRISPR/Cas system. Cell Res. 2013;23(10):1229–1232. doi:10.1038/cr.2013.11423958582
   PubMed Web of Science ®Google Scholar
• Li D, Qiu Z, Shao Y, et al. Heritable gene targeting in the mouse and rat using a CRISPR-Cas system. Nat Biotechnol. 2013;31(8):681–683. doi:10.1038/nbt.266123929336
   PubMed Web of Science ®Google Scholar
• Gratz SJ, Cummings AM, Nguyen JN, et al. Genome engineering of Drosophila with the CRISPR RNA-Guided Cas9 nuclease. Genetics. 2013;194(4):1029–1035. doi:10.1534/genetics.113.15271023709638
   PubMed Web of Science ®Google Scholar
• Friedland AE, Tzur YB, Esvelt KM, Colaiácovo MP, Church GM, Calarco JA. Heritable genome editing in C. elegans via a CRISPR-Cas9 system. Nat Methods. 2013;10(8):741–743. doi:10.1038/nmeth.253223817069
   PubMed Web of Science ®Google Scholar
• Shipman SL, Nivala J, Macklis JD, Church GM. Molecular recordings by directed CRISPR spacer acquisition. Science. 2016;353(6298):aaf1175. doi:10.1126/science.aaf117527284167
   PubMed Web of Science ®Google Scholar
• Makarova KS, Wolf YI, Alkhnbashi OS, et al. An updated evolutionary classification of CRISPR–Cas systems. Nat Rev Microbiol. 2015;13:722. doi:10.1038/nrmicro356926411297
   PubMed Web of Science ®Google Scholar
• Horvath P, Barrangou R. CRISPR/Cas, the immune system of bacteria and archaea. Science. 2010;327(5962):167–170. doi:10.1126/science.117955520056882
   PubMed Web of Science ®Google Scholar
• Makarova KS, Grishin NV, Shabalina SA, Wolf YI, Koonin EV. A putative RNA-interference-based immune system in prokaryotes: computational analysis of the predicted enzymatic machinery, functional analogies with eukaryotic RNAi, and hypothetical mechanisms of action. Biol Direct. 2006;1(1):7. doi:10.1186/1745-6150-1-716545108
   PubMed Web of Science ®Google Scholar
• Brouns SJ, Jore MM, Lundgren M, et al. Small CRISPR RNAs guide antiviral defense in prokaryotes. Science. 2008;321(5891):960–964. doi:10.1126/science.115968918703739
   PubMed Web of Science ®Google Scholar
• Makarova KS, Haft DH, Barrangou R, et al. Evolution and classification of the CRISPR–Cas systems. Nat Rev Microbiol. 2011;9(6):467. doi:10.1038/nrmicro257721552286
   PubMed Web of Science ®Google Scholar
• Makarova KS, Wolf YI, Iranzo J, et al. Evolutionary classification of CRISPR–Cas systems: a burst of class 2 and derived variants. Nat Rev Microbiol. 2020;18(2):67–83. doi:10.1038/s41579-019-0299-x31857715
   PubMed Web of Science ®Google Scholar
• Semenova E, Jore MM, Datsenko KA, et al. Interference by clustered regularly interspaced short palindromic repeat (CRISPR) RNA is governed by a seed sequence. Proc Natl Acad Sci. 2011;108(25):10098–10103. doi:10.1073/pnas.110414410821646539
   PubMed Web of Science ®Google Scholar
• Mojica FJ, Díez-Villaseñor C, García-Martínez J, Almendros C. Short motif sequences determine the targets of the prokaryotic CRISPR defence system. Microbiology. 2009;155(3):733–740. doi:10.1099/mic.0.023960-019246744
   PubMed Web of Science ®Google Scholar
• Wiedenheft B, van Duijn E, Bultema JB, et al. RNA-guided complex from a bacterial immune system enhances target recognition through seed sequence interactions. Proc Natl Acad Sci. 2011;108(25):10092–10097. doi:10.1073/pnas.110271610821536913
   PubMed Web of Science ®Google Scholar
• Marraffini LA, Sontheimer EJ. Self versus non-self discrimination during CRISPR RNA-directed immunity. Nature. 2010;463(7280):568. doi:10.1038/nature0870320072129
   PubMed Web of Science ®Google Scholar
• Bikard D, Euler CW, Jiang W, et al. Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. Nat Biotechnol. 2014;32:1146. doi:10.1038/nbt.304325282355
   PubMed Web of Science ®Google Scholar
• Citorik RJ, Mimee M, Lu TK. Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. Nat Biotechnol. 2014;32:1141. doi:10.1038/nbt.301125240928
   PubMed Web of Science ®Google Scholar
• Gomaa AA, Klumpe HE, Luo ML, Selle K, Barrangou R, Beisel CL. Programmable removal of bacterial strains by use of genome-targeting CRISPR-Cas systems. mBio. 2014;5(1):e00928–13. doi:10.1128/mBio.00928-1324473129
   PubMed Web of Science ®Google Scholar
• Hale Caryn R, Majumdar S, Elmore J, et al. Essential features and rational design of CRISPR RNAs that function with the Cas RAMP module complex to cleave RNAs. Mol Cell. 2012;45(3):292–302. doi:10.1016/j.molcel.2011.10.02322227116
   PubMed Web of Science ®Google Scholar
• Shmakov S, Smargon A, Scott D, et al. Diversity and evolution of class 2 CRISPR–Cas systems. Nat Rev Microbiol. 2017;15(3):169. doi:10.1038/nrmicro.2016.18428111461
   PubMed Web of Science ®Google Scholar
• Fonfara I, Richter H, Bratovič M, Le Rhun A, Charpentier E. The CRISPR-associated DNA-cleaving enzyme Cpf1 also processes precursor CRISPR RNA. Nature. 2016;532(7600):517–521. doi:10.1038/nature1794527096362
   PubMed Web of Science ®Google Scholar
• East-Seletsky A, O’Connell MR, Knight SC, et al. Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection. Nature. 2016;538(7624):270–273. doi:10.1038/nature1980227669025
   PubMed Web of Science ®Google Scholar
• Liu L, Li X, Wang J, et al. Two distant catalytic sites are responsible for C2c2 RNase activities. Cell. 2017;168(1–2):121–34. e12. doi:10.1016/j.cell.2016.12.03128086085
   PubMed Web of Science ®Google Scholar
• Chylinski K, Makarova KS, Charpentier E, Koonin EV. Classification and evolution of type II CRISPR-Cas systems. Nucleic Acids Res. 2014;42(10):6091–6105. doi:10.1093/nar/gku24124728998
   PubMed Web of Science ®Google Scholar
• Briner AE, Barrangou R. Guide RNAs: a glimpse at the sequences that drive CRISPR–Cas systems. Cold Spring Harb Protoc. 2016;2016(7):pdb.top090902. doi:10.1101/pdb.top090902
   Google Scholar
• Faure G, Shmakov SA, Makarova KS, et al. Comparative genomics and evolution of trans-activating RNAs in Class 2 CRISPR-Cas systems. RNA Biol. 2019;16(4):435–448. doi:10.1080/15476286.2018.149333130103650
   PubMed Web of Science ®Google Scholar
• Chyou T-Y, Brown CM. Prediction and diversity of tracrRNAs from type II CRISPR-Cas systems. RNA Biol. 2019;16(4):423–434. doi:10.1080/15476286.2018.149828129995560
   PubMed Web of Science ®Google Scholar
• Burley KM, Sedgley CM. CRISPR-Cas, a prokaryotic adaptive immune system, in endodontic, oral, and multidrug-resistant hospital-acquired enterococcus faecalis. J Endod. 2012;38(11):1511–1515. doi:10.1016/j.joen.2012.07.00423063226
   PubMed Web of Science ®Google Scholar
• Lindenstrauß AG, Pavlovic M, Bringmann A, Behr J, Ehrmann MA, Vogel RF. Comparison of genotypic and phenotypic cluster analyses of virulence determinants and possible role of CRISPR elements towards their incidence in Enterococcus faecalis and Enterococcus faecium. Syst Appl Microbiol. 2011;34(8):553–560. doi:10.1016/j.syapm.2011.05.00221943678
   PubMed Web of Science ®Google Scholar
• Palmer KL, Gilmore MS. Multidrug-resistant enterococci lack CRISPR-cas. mBio. 2010;1(4):e00227–10. doi:10.1128/mBio.00227-1021060735
   PubMed Web of Science ®Google Scholar
• Manson JM, Hancock LE, Gilmore MS. Mechanism of chromosomal transfer of Enterococcus faecalis pathogenicity island, capsule, antimicrobial resistance, and other traits. Proc Natl Acad Sci. 2010;107(27):12269–12274. doi:10.1073/pnas.100013910720566881
   PubMed Web of Science ®Google Scholar
• Gilmore MS, Clewell DB. The Enterococci: Pathogenesis, Molecular Biology, and Antibiotic Resistance. Zondervan; 2002.
   Google Scholar
• Roberts AP, Mullany P. A modular master on the move: the Tn916 family of mobile genetic elements. Trends Microbiol. 2009;17(6):251–258. doi:10.1016/j.tim.2009.03.00219464182
   PubMed Web of Science ®Google Scholar
• Flannagan SE, Chow JW, Donabedian SM, et al. Plasmid content of a vancomycin-resistant Enterococcus faecalis isolate from a patient also colonized by Staphylococcus aureus with a VanA phenotype. Antimicrob Agents Chemother. 2003;47(12):3954–3959. doi:10.1128/AAC.47.12.3954-3959.200314638508
   PubMed Web of Science ®Google Scholar
• Zhu W, Clark NC, McDougal LK, Hageman J, McDonald LC, Patel JB. Vancomycin-resistant Staphylococcus aureus isolates associated with Inc18-like vanA plasmids in Michigan. Antimicrob Agents Chemother. 2008;52(2):452–457. doi:10.1128/AAC.00908-0718056272
   PubMed Web of Science ®Google Scholar
• Marraffini LA, Sontheimer EJ. CRISPR interference limits horizontal gene transfer in staphylococci by targeting DNA. Science. 2008;322(5909):1843–1845. doi:10.1126/science.116577119095942
   PubMed Web of Science ®Google Scholar
• Díez-Villaseñor C, Almendros C, García-Martínez J, Mojica FJ. Diversity of CRISPR loci in Escherichia coli. Microbiology. 2010;156(5):1351–1361. doi:10.1099/mic.0.036046-0
   Web of Science ®Google Scholar
• Touchon M, Rocha EP. The small, slow and specialized CRISPR and anti-CRISPR of Escherichia and Salmonella. PLoS One. 2010;5(6):e11126. doi:10.1371/journal.pone.001112620559554
   PubMed Web of Science ®Google Scholar
• Bondy-Denomy J, Garcia B, Strum S, et al. Multiple mechanisms for CRISPR–Cas inhibition by anti-CRISPR proteins. Nature. 2015;526(7571):136. doi:10.1038/nature1525426416740
   PubMed Web of Science ®Google Scholar
• Pawluk A, Bondy-Denomy J, Cheung VH, Maxwell KL, Davidson AR. A new group of phage anti-CRISPR genes inhibits the type IE CRISPR-Cas system of Pseudomonas aeruginosa. MBio. 2014;5(2):e00896–14. doi:10.1128/mBio.00896-1424736222
   PubMed Web of Science ®Google Scholar
• Pawluk A, Staals RH, Taylor C, et al. Inactivation of CRISPR-Cas systems by anti-CRISPR proteins in diverse bacterial species. Nat Microbiol. 2016;1(8):16085. doi:10.1038/nmicrobiol.2016.8527573108
   PubMed Web of Science ®Google Scholar
• Vercoe RB, Chang JT, Dy RL, et al. Cytotoxic chromosomal targeting by CRISPR/Cas systems can reshape bacterial genomes and expel or remodel pathogenicity islands. PLoS Genet. 2013;9(4):e1003454. doi:10.1371/journal.pgen.100345423637624
   PubMed Web of Science ®Google Scholar
• Esvelt KM, Smidler AL, Catteruccia F, Church GM. Concerning RNA-guided gene drives for the alteration of wild populations. eLife. 2014;3:e03401. doi:10.7554/eLife.0340125035423
   PubMed Web of Science ®Google Scholar
• Kim J-S, Cho D-H, Park M, et al. CRISPR/Cas9-mediated re-sensitization of antibiotic-resistant Escherichia coli harboring extended-spectrum beta-lactamases. J Microbiol Biotechnol. 2016;26(2):394–401. doi:10.4014/jmb.1508.0808026502735
   PubMed Web of Science ®Google Scholar
• Melnikov AA, Tchernov AP, Fodor I, Bayev AA. Lambda phagemids and their transducing properties. Gene. 1984;28(1):29–35. doi:10.1016/0378-1119(84)90084-26234200
   PubMed Web of Science ®Google Scholar
• Ubukata K, Nonoguchi R, Matsuhashi M, Konno M. Expression and inducibility in Staphylococcus aureus of the mecA gene, which encodes a methicillin-resistant S. aureus-specific penicillin-binding protein. J Bacteriol. 1989;171(5):2882–2885.2708325
   PubMed Web of Science ®Google Scholar
• Isnard C, Malbruny B, Leclercq R, Cattoir V. Genetic basis for in vitro and in vivo resistance to lincosamides, streptogramins A, and pleuromutilins (LSAP phenotype) in Enterococcus faecium. Antimicrob Agents Chemother. 2013;57(9):4463–4469. doi:10.1128/AAC.01030-1323836170
   PubMed Web of Science ®Google Scholar
• Rasheed JK, Anderson GJ, Yigit H, et al. Characterization of the extended-spectrum β-lactamase reference strain, Klebsiella pneumoniae K6 (ATCC 700603), which produces the novel enzyme SHV-18. Antimicrob Agents Chemother. 2000;44(9):2382–2388. doi:10.1128/AAC.44.9.2382-2388.200010952583
   PubMed Web of Science ®Google Scholar
• Rasheed JK, Kitchel B, Zhu W, et al. New Delhi Metallo-β-Lactamase–producing Enterobacteriaceae, United States. Emerg Infect Dis. 2013;19(6):870. doi:10.3201/eid1906.12151523731823
   PubMed Web of Science ®Google Scholar
• Jacoby GA. Mechanisms of resistance to quinolones. Clin Infect Dis. 2005;41(Supplement_2):S120–S6. doi:10.1086/42805215942878
   PubMed Web of Science ®Google Scholar
• Patnaik S, Gupta KC. Novel polyethylenimine-derived nanoparticles for in vivo gene delivery. Expert Opin Drug Deliv. 2013;10(2):215–228. doi:10.1517/17425247.2013.74496423252504
   PubMed Web of Science ®Google Scholar
• Chung HJ, Hong CA, Lee SH, Jo SD, Park TG. Reducible siRNA dimeric conjugates for efficient cellular uptake and gene silencing. Bioconjug Chem. 2011;22(2):299–306. doi:10.1021/bc100438m21222435
   PubMed Web of Science ®Google Scholar
• Zuris JA, Thompson DB, Shu Y, et al. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat Biotechnol. 2015;33(1):73. doi:10.1038/nbt.308125357182
   PubMed Web of Science ®Google Scholar
• Wang M, Zuris JA, Meng F, et al. Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles. Proc Natl Acad Sci. 2016;113(11):2868–2873. doi:10.1073/pnas.152024411326929348
   PubMed Web of Science ®Google Scholar
• Pérez-Mendoza D. de la Cruz F. Escherichia coli genes affecting recipient ability in plasmid conjugation: are there any? BMC Genom. 2009;10(1):71. doi:10.1186/1471-2164-10-71
   Web of Science ®Google Scholar
• Smillie C, Garcillán-Barcia MP, Francia MV, Rocha EP, de la Cruz F. Mobility of plasmids. Microbiol Mol Biol Rev. 2010;74(3):434–452. doi:10.1128/MMBR.00020-1020805406
   PubMed Web of Science ®Google Scholar
• Oliveira PH, Touchon M, Rocha EP. The interplay of restriction-modification systems with mobile genetic elements and their prokaryotic hosts. Nucleic Acids Res. 2014;42(16):10618–10631. doi:10.1093/nar/gku73425120263
   PubMed Web of Science ®Google Scholar
• Jain A, Srivastava P. Broad host range plasmids. FEMS Microbiol Lett. 2013;348(2):87–96. doi:10.1111/1574-6968.1224123980652
   PubMed Web of Science ®Google Scholar
• Hausner M, Wuertz S. High rates of conjugation in bacterial biofilms as determined by quantitative in situ analysis. Appl Environ Microbiol. 1999;65(8):3710–3713. doi:10.1128/AEM.65.8.3710-3713.199910427070
   PubMed Web of Science ®Google Scholar
• Peters JM, Koo B-M, Patino R, et al. Enabling genetic analysis of diverse bacteria with Mobile-CRISPRi. Nat Microbiol. 2019;4(2):244–250. doi:10.1038/s41564-018-0327-z30617347
   PubMed Web of Science ®Google Scholar
• Brophy JA, Triassi AJ, Adams BL, et al. Engineered integrative and conjugative elements for efficient and inducible DNA transfer to undomesticated bacteria. Nat Microbiol. 2018;3(9):1043–1053. doi:10.1038/s41564-018-0216-530127494
   PubMed Web of Science ®Google Scholar
• López-Igual R, Bernal-Bayard J, Rodríguez-Patón A, Ghigo J-M MD. Engineered toxin–intein antimicrobials can selectively target and kill antibiotic-resistant bacteria in mixed populations. Nat Biotechnol. 2019;37(7):755–760. doi:10.1038/s41587-019-0105-330988505
   PubMed Web of Science ®Google Scholar
• Hamilton TA, Pellegrino GM, Therrien JA, et al. Efficient inter-species conjugative transfer of a CRISPR nuclease for targeted bacterial killing. Nat Commun. 2019;10(1):4544. doi:10.1038/s41467-019-12448-331586051
   PubMed Web of Science ®Google Scholar
• Kaper JB, Nataro JP, Mobley HL. Pathogenic escherichia coli. Nat Rev Microbiol. 2004;2(2):123. doi:10.1038/nrmicro81815040260
   PubMed Web of Science ®Google Scholar
• Sonnenburg JL, Fischbach MA. Community health care: therapeutic opportunities in the human microbiome. Sci Transl Med. 2011;3(78):78ps12. doi:10.1126/scitranslmed.3001626
   Web of Science ®Google Scholar
• Gray GS, Fitch WM. Evolution of antibiotic resistance genes: the DNA sequence of a kanamycin resistance gene from Staphylococcus aureus. Mol Biol Evol. 1983;1(1):57–66. doi:10.1093/oxfordjournals.molbev.a0402986100986
   PubMed Web of Science ®Google Scholar
• Desbois AP, Coote PJ. Utility of greater wax moth larva (Galleria mellonella) for evaluating the toxicity and efficacy of new antimicrobial agents. Adv Appl Microbiol. 2012;78:25–53. Elsevier22305092
   PubMed Web of Science ®Google Scholar
• Kiga K, Tan X-E, Ibarra-Chávez R, et al. Development of CRISPR-Cas13a-based antimicrobials capable of sequence-specific killing of target bacteria. bioRxiv. 2019;808741.
   Google Scholar
• Roach DR, Leung CY, Henry M, et al. Synergy between the host immune system and bacteriophage is essential for successful phage therapy against an acute respiratory pathogen. Cell Host Microbe. 2017;22(1):38–47. e4. doi:10.1016/j.chom.2017.06.01828704651
   PubMed Web of Science ®Google Scholar